---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005600"
form_type: "8-K"
ticker: null
cik: "0001358762"
company_name: "REATA PHARMACEUTICALS INC"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:21:21.822985+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Reata Pharmaceuticals amends bylaws to update director nomination procedures and exclusive forum provisions

## Summary
- Board of Directors approved Third Amended and Restated Bylaws effective March 1, 2023.
- Amendments revise procedures and disclosure requirements for director nominations to comply with SEC Rule 14a-19.
- Bylaws designate federal district courts as exclusive forum for Securities Act of 1933 claims.
- Updates made to indemnification provisions and other administrative changes to conform with Delaware General Corporation Law.
- Exhibit 3.1 filed with the 8-K contains the full text of the Amended and Restated Bylaws.

## SEC filing metadata
- accession: 0000950170-23-005600
- form_type: 8-K
- cik: 0001358762
- company_name: REATA PHARMACEUTICALS INC
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1358762/000095017023005600/0000950170-23-005600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1358762/000095017023005600/reta-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005600
- JSON: https://secwatch.observer/filing/0000950170-23-005600.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005600.txt

## Key facts
- Governance Changes
  REATA PHARMACEUTICALS INC: 董事会批准了第三次修订和重述的公司章程，包括修改董事提名程序、通知程序、专属法庭条款、赔偿条款及其他行政性变更。 (effective 2023-03-01).
  - Change: bylaw amendment
  - Effective: 2023-03-01
  source text: On March 1, 2023, the Board of Directors of Reata Pharmaceuticals, Inc. (the “Company”) approved the Company’s Third Amended and Restated Bylaws (“Amended and Restated Bylaws”), effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358762/000095017023005600/0000950170-23-005600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.